Wednesday 15th February 2017
|Text too small?|
Cancer diagnostics company Pacific Edge has undertaken an $8 million share placement to institutional and other select investors in New Zealand in order to shore up its balance sheet.
The placement was undertaken at no discount to market with investors subscribing at 50 cents per share, the trading price on Tuesday.
"While the company has sufficient cash on hand of approximately $9 million for its immediate growth requirements, the new investments provides additional support for Pacific Edge to drive its commercial growth," it said.
Pacific Edge has a range of diagnostic and prognostic tests for better detection and management of bladder cancer, known as Cxbladder tests. The company claims its non-invasive tests are more accurate than other urine-based cancer tests.
The Dunedin-based company said it is generating increasing sales revenue, with a 162 percent jump in operating revenue in the last financial year. It also noted test throughput is increasing as a greater number of urologists trial and purchase Cxbladder tests.
Pacific Edge chief executive David Darling also said the company was starting to see some real progress, particularly in the United States where it is investing in infrastructure and new products.
He said the company's capital requirements for its growth strategy this year will be similar to last and the additional funds "will be used to progress and expedite our commercial goal of getting to a cash flow position as fast as possible, with our focus squarely on the USA."
No comments yet
NZ shares fell on global growth concerns
New Zealand dollar becalmed ahead of CPI data
Billionaire Aussie miner moves businesses to NZ in 'quixotic' CER gambit
RBNZ plucks bank capital numbers out of the air: Reddell
Genesis coal burn reached 5-yr high in 'unprecedented' conditions
Govt part-funds another $11m of low-emissions transport projects
January 22nd Morning Report
NZ dollar stalled ahead of CPI data; IMF trims global outlook
MARKET CLOSE: NZ stocks gain; investors seek value ahead of earnings season
NZ dollar drifts lower ahead of CPI; China GDP as expected